Last reviewed · How we verify

Cassiopea SpA — Portfolio Competitive Intelligence Brief

Cassiopea SpA pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Clascoterone 5% solution Clascoterone 5% solution phase 3 Androgen receptor antagonist Androgen receptor (AR) Dermatology
CB-03-01 cream, 1% CB-03-01 cream, 1% phase 3 Androgen receptor antagonist Androgen receptor (AR) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AEterna Zentaris · 1 shared drug class
  2. CHU de Quebec-Universite Laval · 1 shared drug class
  3. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  4. Orion Corporation, Orion Pharma · 1 shared drug class
  5. Pfizer · 1 shared drug class
  6. Santa Chiara Hospital · 1 shared drug class
  7. Suzhou Kintor Pharmaceutical Inc, · 1 shared drug class
  8. The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cassiopea SpA:

Cite this brief

Drug Landscape (2026). Cassiopea SpA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cassiopea-spa. Accessed 2026-05-13.

Related